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ABSTRACT 
 
Background:  The death of a patient under dental intravenous sedation in New 
South Wales, Australia, in 2002 while being treated by a dentist with appropriate 
training in intravenous conscious sedation (ICS), (Graduate Diploma in Clinical 
Dentistry; Conscious Sedation and Pain Control, University of Sydney) has once 
again brought into question the safety of ICS. The cause of death was 
irreversible cerebral hypoxia following a cardiac arrest, which was precipitated by 
numerous periods of ever-deepening hypoxaemia.  
 
Aim: This retrospective, quality-assurance audit investigated whether safe 
oxygen saturation levels could be maintained during single operator/sedationist 
dental sedations, when operating within the joint Royal Australasian College of 
Dental Surgeons (RACDS) and Australian and New Zealand College of 
Anaesthetists (ANZCA) PS21 guidelines for conscious sedation.  
 
Methodology: Safe oxygen saturation levels were defined as pulse oximeter 
readings of 94% and above. The recording of two or more readings of less than 
94% during a sedation procedure was defined as the outcome of interest. The 
association of the variables of age (eighteen and over), gender, weight, the 
American Society of Anesthesiologists (ASA) Classification I or II and the use of 
propofol in addition to midazolam and fentanyl, to low saturations, was examined. 
Two sub-cohorts were randomly generated: 1,750 patients were sedated with 
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midazolam and fentanyl and 1,750 patients received propofol, in sub-anaesthetic 
increments, in addition to midazolam and fentanyl. All patients received 
supplemental oxygen.  Initial sedation was established using midazolam and 
fentanyl in both sub-cohorts. The second sub-cohort received sub-anaesthetic 
increments of propofol during times of noxious stimulation. Statistical analysis of 
the data used cross-tabulation of the variables by outcome, an associated chi-
squared test and corresponding logistic regression analysis, together with odds 
ratio (OR) and a 95% confidence interval (95%CI).  
 
Results: Patient exposure to two or more oxygen de-saturations below 94% was 
uncommon. The null hypothesis could not be rejected because there was no 
significant difference between the saturation levels recorded for each sub-cohort 
(µ1 - µ2 = 0), where µ1 was the cohort that received propofol in addition to 
midazolam and fentanyl, and µ2 was the cohort that received midazolam and 
fentanyl only. Analysis of the two population groups found them to be quite 
different in make-up. Had the two population groups been similar in make-up, 
then µ1 - µ2 may not have equaled 0, and the outcome of the hypothesis test may 
have been to reject H0.  The variables that were significantly associated with low 
saturations were age, gender and weight. The data showed that males were 
three times more likely than females to experience low saturations. Patients 45 
years and older were nearly eight times more likely to experience low saturations 
than patients 25 years or younger. Patients classified as being in the gender-
specific high weight group were twice as likely to experience low saturations than 
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those in the low and medium weight groups. Neither the dose of midazolam, nor 
the additional use of propofol were significant risk factors, even after adjusting for 
the variables of age, gender and weight. ASA Classification (I or II) was not a 
determinant of risk. 
 
Conclusion: Within the limitations of this study, the data support that a single 
operator/sedationist, working within the RACDS/ANZCA document PS21 
guidelines, and supported by a team of experienced dental nurses, can 
consistently maintain safe oxygen saturation levels when working on ASA I or II 
patients, regardless of age, gender, gender-specific weight, dose of midazolam, 
or the additional use of propofol.   
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SECTION 1: REVIEW OF THE LITERATURE 
 
INTRODUCTION 
 
Intravenous conscious sedation (ICS) is a term used to describe the 
administration of intravenous sedative drug(s) in order to alter a patientʼs state of 
consciousness so that a medical or dental procedure can be carried out that 
would not normally be tolerated in the fully conscious state. The alteration in 
consciousness should be such that spontaneous, effective ventilation is 
maintained, as well as the gag and cough reflexes and a level of communication 
appropriate to the patient. In the dental setting, local anaesthetic would also be 
used to provide analgesia.  
 
The ideal intravenous sedative should provide relaxation, anxiolysis, amnesia 
and analgesia. It should have a rapid on-set and rapid recovery and be 
reversible, should there be a need for this requirement. In addition, it should not 
cause any significant haemodynamic change, or suppression of respiratory drive. 
The ideal drug remains elusive and often a combination of drugs is used in an 
attempt to provide ideal sedation.  
 
Historically, many drugs have been used to provide ICS. These include the 
benzodiazepine valium (diazepam), the barbiturate methohexital, the narcotic 
agents pethidine and pentazocine and the dissociative anaesthetic ketamine. 
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None of these drugs meet the requirements of the ideal sedative and this has 
lead to the development of newer agents.  The most commonly used modern day 
drugs are the benzodiazepine midazolam, the narcotic fentanyl, and the hypnotic 
agent, propofol. Midazolam may be used as the sole agent (Runes & Ström 
1996) or together with a narcotic (Milgrom, Beirne, Fiset, Weinstein, Tay & Martin 
1993). Propofol may be used as sole agent (Leitch, Sutcliffe & Kennt 2003) or in 
combination with midazolam and fentanyl (Perrott, Yuen & Dodson 2003). Whilst 
these drugs are an improvement on the older agents, they may still cause 
profound respiratory depression and delayed recovery and therefore, the 
potential for morbidity or mortality remains. ICS may expose the patient to 
anaesthetic risk should over-sedation occur. It is therefore important to be able to 
measure the safety of modern day ICS and define risk factors.  
 
A review of the literature was undertaken to examine the use of midazolam, 
fentanyl and propofol to provide modern-day ICS, both separately and in 
combination. A review of articles and papers relating to the safety and the 
associated risk factors of intravenous conscious sedation was also undertaken.  
 
Much has been published about the medical use of intravenous sedation (Lytle & 
Stamper 1989; DʼEramo 1999; Rozario, Sloper & Sheridan 2008). 
Gastroenterologists, cardiologists, intensivists and radiologists all routinely use 
ICS. Medical sedations may differ in many ways from dental sedations. For 
example, medical sedations often do not utilize local anaesthesia to cover painful 
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aspects of the procedure. This lack of pain control may require much higher 
doses of sedative drug(s) to mask the pain, which in the dental setting, would be 
provided by local anaesthetic.  
 
The range in the health status (ASA classification) of patients undergoing medical 
procedures is much broader than dental patients treated in the private practice 
setting. Dental sedations in the private setting are only performed on ASA I or II 
patients, whilst medical sedations additionally may include ASA III and IV 
patients, with associated increased risk.   
 
Medical sedations include a wider age-range (from very young paediatric to very 
old geriatric patients) than would normally be treated in the private practice dental 
setting. Jastak & Peskin (1991) noted a higher incidence of adverse outcomes in 
the dental setting with extremes of age. 
 
For the reasons listed above, data obtained from medical sedations may be quite 
different from ICS data generated in the dental setting. Therefore, dentists need 
to harvest and generate their own data, specific to dental sedation, to which we 
can refer.  
 
In the dental setting, hypoxaemia is the most likely risk factor associated with an 
adverse outcome (Hovagin, Vitkun, Manecke & Reiner 1989; Jastak & Peskin 
1991). A review of the literature indicates that most dental references use lack of 
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morbidity (for example, nausea, vomiting, syncope, delayed recovery) or 
mortality, rather than recorded saturation levels as a measure of safety.  Only 
one dental reference (Walton, Boyle & Thompson 1991) was found where 
oxygen saturation levels recorded during ICS were used as a measurement of 
safety.  
 
Pain and anxiety management has always been an integral part of dentistry. Two 
recent UK surveys reported that over half of the UKʼs adult population is anxious 
about dental treatment. This in turn leads to avoidance of treatment, with irregular 
attendance. Dentists too, reported that treating nervous patients was a major 
source of their personal stress. Most dentists surveyed were keen to deal with 
this problem and nearly three quarters of the dentists surveyed felt there was a 
need for sedation and for formal training in this area of dentistry (Adult Dental 
Health Surveys UK, 1988 & 1998). Leitch and Macpherson (2007) reviewed the 
current state of sedation care in dentistry.  The authors report on the use of oral 
sedation with benzodiazepines, inhalation sedation, and intravenous sedation 
with both midazolam and propofol.  A positive outcome using propofol was noted 
as well as the fact that further research in this area of intravenous sedation is 
needed.  
 
Dentists generally use local anaesthetic to cover painful procedures. Some 
procedures, however, require greater levels of pain and anxiety control than can 
be provided by local anaesthetic alone.  Coulthard and Craig (1997) suggest that 
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intravenous sedation is not a replacement for a caring and sympathetic attitude 
towards the patient, but rather a useful adjunct along with effective local 
anaesthetic techniques. They emphasise the importance of monitoring and post-
graduate training.  
 
Many authors (Kingon 1990; Milgrom, Beirne, Fiset, Weinstein, Tay & Martin 
1993; Perrott, Yuen & Dodson 2003; Rogers 2005) report on the very positive 
patient response to treatment carried out under intravenous sedation, as well as 
an improved working environment for the proceduralist.  
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GUIDELINES FOR DENTAL SEDATION 
 
The early nineteen nineties saw the introduction of guidelines for dental 
intravenous sedation procedures in Australia. These guidelines evolved as a 
result of discussions between the Australian and New Zealand College of 
Anaesthetists (ANZCA) and the Royal Australasian College of Dental Surgeons 
(RACDS), along with members of the newly formed Sedation Clinic at Westmead 
hospital and representatives of the Australian Society of Dental Anaesthesiology 
(ASDA).  This original joint policy document was called P21 (1996) and after 
review in 2003, became PS21 (Appendix1). PS21 defined accepted Australian 
standards for in-surgery conscious dental sedation. The guidelines cover general 
principles that include the appropriate qualifications of the dentist sedationist, 
staffing requirements and training, facilities, monitoring, oxygenation, commonly 
used drugs, required specialised equipment and post-operative discharge. 
Emergency equipment and emergency drugs are also defined. 
 
In April 2010, ANZCA unilaterally disestablished PS21 and a revised version of 
PS9 was published which recommends guidelines for both medical and dental 
sedation procedures. The RACDS later became signatory to PS9, despite strong 
opposition from ASDA and many Australian and New Zealand dentists. In 
November 2010, the Australian Dental Association, with input from ASDA 
introduced its own guidelines for ICS in Australia. 
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PHARMACOLOGY OF AGENTS CURRENTLY USED TO PROVIDE 
INTRAVENOUS CONSCIOUS SEDATION IN AUSTRALIA 
 
Three intravenous sedative agents are predominantly used to provide ICS in 
Australia.  These include midazolam, fentanyl and propofol. The composition, 
actions, pharmacodynamics, pharmacokinetics, indications, contraindications 
and dosage of each drug (MIMS Annual 2010) are briefly reviewed below: 
 
(i) Midazolam:   
 
(a)  Composition: The benzodiazepine midazolam is marketed by 
Roche as Hypnovel in Australia. Its chemical name is 8-chloro-6-(2-
fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4] benzodiazepine. 
 
(b)  Actions: Midazolam is a short acting central nervous system 
depressant that induces sedation, hypnosis, amnesia and 
anaesthesia. 
 
(c)  Pharmacodynamics: Benzodiazepines appear to intensify the 
inhibitory mechanisms mediated by gamma aminobutyric acid (GABA), 
the most common inhibitory neurotransmitter in the brain. When used 
as an IV sedative, sedation is reached within 3 to 5 minutes, 
depending on whether a narcotic has been administered. 
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Approximately two hours are required for full recovery and this period 
may be affected if other drugs are used in combination. Intravenous 
midazolam decreases the sensitivity of the ventilatory response to 
elevated carbon dioxide levels. Midazolam has no other negative 
pulmonary effects. At levels used for sedation, midazolam has no 
deleterious effects on cardiac haemodynamics. 
 
(d)  Pharmacokinetics: The pharmacokinetic profile of midazolam in 
humans is linear in the drug range used during intravenous sedation 
procedures. In normal subjects, the drug exhibits a short elimination 
half-life of 1 to 2.8 hours, a large volume of distribution and a rapid 
plasma clearance. The mean absolute bioavailability of midazolam is 
greater than 90%. The drug is rapidly metabolised in the liver with 
subsequent excretion in the urine. Ninety seven percent (97%) of 
midazolam becomes bound to plasma proteins. 
 
(e)  Indications: Midazolam is used widely as an agent for conscious 
intravenous sedation in both dentistry and medicine. It can also be 
used for intravenous induction of anaesthesia, or as a pre-medication 
prior to general anaesthetic induction. 
 
(f) Contraindications: Benzodiazepines are contraindicated in patients 
with acute narrow angle glaucoma and they should not be used on 
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patients who have a hypersensitivity to benzodiazepines.   
 
(g)  Precautions when used in the dental setting: Care should be taken 
to slowly titrate the drug to the desired end point, as there can be a 
wide variation in individual response. Care should also be taken in the 
older patient group, as they tend to be more sensitive to this drug. 
Midazolam has a respiratory depressant effect and therefore, should 
be used with care on patients who suffer any form of pulmonary 
disease. Concomitant use of other central nervous system 
depressants increases the risk of under ventilation or apnoea and this 
factor should be taken into account when multiple agents are used. 
Patients should also be advised not to drive a vehicle or operate a 
machine until the effects of the drug have subsided or until the day 
after the sedative procedure. 
 
(h)  Dosage: Intravenous midazolam should not be administered as a 
single bolus, but slowly, in 1 milligram increments and titrated to the 
desired sedative end point, such as slurring of speech. The initial dose 
should be given over a period of at least two minutes. In healthy adults 
the initial dose is approximately 2.5 milligrams, however, some 
patients may respond to as little as 1 milligram. Further doses of 1 
milligram may be given as necessary to reach the desired end point, 
such as the Verrill sign or ptosis (Donaldson, Harrop & Kliennecht 
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1980). A total dose greater than 5 milligrams is not usually necessary.  
If a narcotic is used in conjunction with the midazolam, the dose of 
midazolam should be lowered by 25 to 30 %. 
 
(i) Overdosage: In the case of overdose, respiration, pulse rate and 
blood pressure should be monitored and general supportive measures 
should be employed. Flumazenil can be used to reverse the effects of 
the midazolam. Caution should be observed when using flumazenil in 
cases of mixed drug overdose such as when midazolam is used in 
combination with fentanyl. Patients who are being treated with 
benzodiazepines for epilepsy should be reversed with caution.   
 
(ii) Fentanyl: 
 
(a) Composition: Fentanyl is an opioid analgesic and is marketed in 
Australia by AstraZeneca Pty Ltd.  Its chemical name is N-(1- 
phenethyl - 4 - piperidyl) propionanilide citrate. 
 
(b) Actions: Fentanyl is a short acting synthetic narcotic and may be 
used during conscious intravenous sedation procedures in conjunction 
with the benzodiazepine midazolam.   
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(c)  Pharmacodynamics: A dose of 100 micrograms of fentanyl is 
approximately equivalent in analgesic activity to 10 milligrams of 
morphine or 75 milligrams of pethidine. The principle therapeutic 
values of fentanyl are analgesia and sedation. Fentanyl interacts with 
opiate receptors, decreasing pain impulse transmission at the spinal 
cord level and higher in the central nervous system. Fentanyl is a 
potent µ-opiate receptor agonist. Fentanyl also causes peripheral 
vasodilation, increasing venous capacitance and decreases venous 
return by depressing the responsiveness of alpha-adrenergic 
receptors. Since it decreases both preload and afterload, it may 
decrease myocardial oxygen demand. Of note is that the respiratory 
depressive effect associated with opioid analgesics may last longer 
than the analgesic effect. Fentanyl appears to have less emetic 
activity than other opioids and less significant histamine release 
occurs with the use of fentanyl. Doses of fentanyl 50 micrograms and 
above may produce apnoea. The duration and degree of respiratory 
depression is dose related. The peak respiratory depressant effect of a 
single intravenous dose of fentanyl is noted 5 to 15 minutes following 
the injection. 
 
(d) Pharmacokinetics: The pharmacokinetics of fentanyl can be 
described by a three-compartment model, with a distribution time of 
1.7 minutes, re-distribution of 13 minutes and a terminal elimination 
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half-life of 219 minutes. The onset of action is almost immediate when 
the drug is given via the intravenous route, however, the maximum 
analgesic and respiratory depressant effects may not be noted for 
several minutes. Duration of action is normally 30 to 60 minutes 
following a single intravenous dose of fentanyl. Fentanyl is primarily 
metabolised in the liver and excreted in the urine. A small amount is 
excreted in the faeces. 
 
(e) Indications: Being a short acting opioid, fentanyl is often useful in 
combination with midazolam during intravenous conscious sedation 
procedures. It may also be useful for pain management in the 
immediate post-operative period. 
 
(f) Contraindications: A known intolerance to fentanyl contraindicates 
its use, as does the common use of monoamine oxidase inhibiters 
(MAOI). Lastly, myasthenia gravis contraindicates the use of fentanyl, 
as this drug may cause muscle rigidity upon intravenous 
administration. 
 
(g) Precautions when used in the dental setting: Fentanyl should be 
used with caution in patients with severe impairment of pulmonary 
function and other forms of chronic obstructive pulmonary disease 
because of the possibility of respiratory depression. Fentanyl should 
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also be used with caution in combination with other central nervous 
system depressant drugs and when used in combination, the dosage 
of fentanyl required will be less than usual. 
 
(h) Dosage: Dosage should be individualised according to age, body 
weight, physical status and the use of other drugs. During intravenous 
conscious sedation, an initial dose of 50 to 100 micrograms is usual.   
 
(i) Overdosage: Respiration may need to be assisted or controlled and 
an adequate airway maintained.  Naloxone, an opioid antagonist, will 
reverse the effects of fentanyl. It should be remembered, however, 
that the duration of respiratory depression may be longer than the 
duration of action of the opioid antagonist and the patient should be 
closely monitored if there is a need to utilise the reversal agent. 
Bradycardia may be treated by administering atropine. Hypertension 
may be treated by administering the appropriate parental fluids and 
repositioning the patient may improve venous-return to the heart. 
 
(iii) Propofol 
 
(a) Composition: The active ingredient is propofol which is present in a 
solution of soy oil, glycerol, egg lecithin, sodium hydroxide and water 
for injection.  The chemical name is 2, 6 – diisopropylphenol.  
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(b) Actions: Propofol is a short acting general anaesthetic agent with a 
rapid onset of action of approximately 30 seconds.  Propofol also has 
a rapid rate of recovery. 
 
(c)  Pharmacodynamics: The mechanism of action of propofol is still 
under investigation, however Trapani, Altomore, Liso, Sanna & Biggio 
(2000) suggest that propofol may have several mechanisms of action, 
both through potentiation of GABA-A receptor activity, thereby slowing 
the channel-closing time, and also by acting as a sodium channel 
blocker. Recent research has also suggested that the 
endocannabinoid system may contribute significantly to propofol's 
anaesthetic action and to its unique properties (Fowler, 2004). The 
clinical effects are proportional to the dose or concentration in the 
blood. These doses are also rate dependent and therefore, low doses 
of propofol given slowly can cause conscious intravenous sedation 
rather than induction of anaesthesia. Low doses (10 - 15mg) of 
propofol, such as would be used during conscious intravenous 
sedation cause minimal reduction in blood pressure, however, the 
higher doses (120 - 200mg) used for general anaesthetic induction 
can cause arterial hypotension and decreased heart rate. Similarly, 
low doses of propofol cause little ventilatory depression, however, at 
higher doses profound respiratory depression can occur. 
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(d) Pharmacokinetics: The pharmacokinetics of propofol follows a 
three compartment open model (Cherruault & Sarin, 1986), with the 
compartments being the plasma; superficial, rapidly equilibrating 
tissues; and deeper, more slowly equilibrating tissues. Following an 
intravenous bolus dose, there is rapid equilibration between the 
plasma and the highly perfused tissue of the brain, thus accounting for 
the rapid onset of anaesthesia. Plasma levels initially decline rapidly 
as a result of both distribution and metabolic clearance. The initial re-
distribution half-life is between two and four minutes, followed by a 
rapid elimination phase with a half-life of 30 to 60 minutes and 
followed by a slower final phase, representative of redistribution and 
metabolism of propofol from poorly perfused tissue. Accumulation may 
occur if higher than necessary infusion rates are used. Propofol is 
primarily metabolised by the liver and excreted via the urine. 
 
(e) Indications: Propofol may be used as a general anaesthetic 
induction agent. It may also be used as a short acting intravenous 
anaesthetic agent in adults and children.  Propofol may be used for 
monitored conscious sedation, as sole agent or in combination with a 
benzodiazepine and opioid. 
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(f) Contraindications: Known allergy to propofol or any of the other 
ingredients contained in the solution.  In the dental setting, when 
propofol is used for ICS, the patient should be continuously monitored 
by a person not involved in the conduct of the surgical or diagnostic 
procedure.  Facilities for maintenance of the patientʼs airway should be 
readily available including oxygen and the ability to provide positive 
pressure ventilation.  As is the case with midazolam, elderly patients 
may be more sensitive to propofol and monitoring during the 
procedure and during the recovery period should be in accordance 
with the needs of the patient. 
 
(g) Dosage: Most patients will require 0.5 to 1 milligram per kilogram 
over one to five minutes for the onset of sedation.  Maintenance of 
sedation may be accomplished by titrating the infusion to the desired 
level of sedation, Most patients will require 1.5 to 3 milligram per 
kilogram per hour.  In the older patient, the dose requirement for 
induction of sedation is reduced. 
 
(h) Overdosage: There is no reversal agent for propofol and overdose 
is likely to cause cardio-respiratory depression.  Respiratory 
depression should be treated by artificial ventilation with oxygen.  
Cardiovascular depression would require fluids, as well as 
repositioning of the patient (head down, legs raised).  
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INTRAVENOUS CONSCIOUS SEDATION: REGULATION, TRAINING AND 
TECHNIQUES USED IN AUSTRALIA 
 
Dentists are required to be registered and approved by the Dental Board of 
Australia (DBA) to provide ICS. Registration as a dentist in itself is no longer a 
sufficient requirement to practise intravenous sedation and it is now an additional 
endorsement. The majority of dental practitioners carrying out ICS procedures 
are graduates of the post-graduate Diploma in Clinical Dentistry (Conscious 
Sedation and Pain Control), University of Sydney. Dentists who have not 
completed the Sydney Diploma require assessment by the DBA, and they may 
be endorsed, based on equivalent overseas training or their experience-base, or 
both. Continuation of registration also requires annual refresher training in 
Advanced Life Support and Emergency Management by a Board approved body 
(Appendix 5).  
 
The graduate Diploma in Clinical Dentistry (Conscious Sedation and Pain 
Control) is a two year part time program that provides in-depth education and 
training in all facets of modern day ICS, including advanced CPR management, 
defibrillation and advanced airway management, such as intubation and the use 
of laryngeal masks (LMAs). Candidates are seconded to the Department of 
Anaesthesia, Westmead Hospital for anaesthetic and sedation training.  The 
most common drugs used include midazolam, fentanyl and the use of sub-
anaesthetic doses of propofol.  
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Depending on the type of procedure being carried out, the sedationist may 
choose to employ one of three drug techniques: single agent, double agent or 
multiple agent. 
 
(i) Single agent: 
(a) Midazolam sedation 
Intravenous midazolam by itself provides sedation, anxiolysis and 
amnesia and when used in conjunction with profound local anaesthesia, 
may provide a safe and effective operating environment. Runes and 
Ström (1996) reported on 372 oral surgery cases that were not suitable 
for treatment under local anaesthetic.   All cases were treated with 
midazolam and local anaesthetic only.  Oxygen saturation levels were 
recorded and in only 10% of cases was there a transient fall below 95%.  
In all but three cases, conscious intravenous sedation allowed the 
procedures to be carried out without resorting to the general anaesthetic 
environment. ICS was found to be a valuable complement to established 
methods for managing anxious patients requiring oral surgery with a very 
low incidence of hypoxaemia. 
 
(b) Propofol sedation 
The benzodiazepine midazolam is the most commonly used intravenous 
sedative. Quine, Bell, McCloy, Charlton, Devlin and Hopkins (1995) 
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reported in the medical literature that up to 13% of patients undergoing 
endoscopy, desaturate to below 80% in the recovery room, following the 
procedure.  Desaturation in the recovery room may be due to the longer 
clinical half-life of midazolam as compared to propofol. Medical mortality 
has been reported in 0.05% of patients with 60% due to hypoxaemia.  
 
An alternative technique to using the longer acting midazolam, is to use 
propofol as the sole sedative agent. Leitch et al (2003) reported on dental 
patient maintained sedation (PMS) using propofol as the sole sedative 
agent. A cohort of 20 patients underwent oral surgical procedures (one 
apicectomy, the rest extractions). A safe and favourable outcome was 
reported for both the patient and the surgeon. Oxygen saturation levels 
were recorded and the mean lowest saturation was 94%. Interestingly, 
supplemental oxygen was not used and was required in only one case 
(ASA III) to correct a single desaturation to 87%. In-surgery sedation 
negates the need to expose the patient to a general anaesthetic, which 
requires a hospital environment that may be hard to access and 
expensive for the uninsured. Both patient and surgeon satisfaction was 
high and this has encouraged the authors to carry out a prospective, 
randomized controlled trial against the more established incremental 
midazolam technique. 
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(ii) Double agent: 
(a) Benzodiazepine and narcotic sedation 
The addition of a narcotic to the benzodiazepine is a well-recognized 
technique. However, it does carry with it the risk of increased apnoea, 
resulting in hypoxaemia. Walton et al (1991) examined whether there 
were any differences in oxygen saturations recorded in patients exposed 
to single drug midazolam sedation, as opposed to those who received a 
synthetic narcotic (nalbuphine), in addition to the benzodiazepine.  
 
A cohort of 40 patients was divided into two groups – one group received 
midazolam only and the second received nalbuphine, in addition.  All 
patients were ASA 1 and all required third molar removal. The study was 
of open design due to the potential dangers of administering the sedation 
agents in a blind fashion. The authors do not mention whether 
supplemental oxygen was used. The cohort that received the narcotic 
was given nalbuphine (0.2mg/kg) first and then two minutes later, the 
midazolam was titrated to the desired patient response. It was noted that 
less midazolam (a mean of 5.3 milligram as compared with a mean of 8.1 
milligram) was required in the combination group.  
 
Sixty percent (60%) of the narcotic and midazolam cohort experienced 
severe episodes of hypoxia (saturations of less than 84%). In addition, 
the combination cohort experienced more frequent and more severe 
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episodes of hypoxaemia.  
 
Fifteen percent (15%) of the midazolam group also experienced 
moderate to severe desaturation and this important implication should 
not be overlooked, because it reinforces the fact that single drug 
techniques may also result in significant desaturations. Of importance too 
is the use of adequate electronic patient monitoring and the ready 
availability of adequate resuscitation equipment. The authors do not 
recommend the combination technique for the inexperienced clinician.  
 
Milgrom et al (1993) reported on 207 intravenous sedations that tested 
the hypothesis that combined drug therapy results in significantly poorer 
safety (as determined by apnoeic events) but no difference in efficacy, 
compared to the single drug approach. All patients were ASA I or II and 
were to undergo wisdom tooth removal. Unlike the study of Walton et al 
(1991), the drugs were prepared by the research pharmacy and 
administered blindly by the anaesthetist. In this study, fentanyl 
(.0014mg/kg) was used rather than nalbuphine, along with midazolam 
(maximum 15 milligram, based on patient response). The authors found 
that the addition of the narcotic resulted in apnoea in 63% of cases, as 
compared to 3% in the midazolam-only group. Interestingly, the authors 
found no difference in patient recall of the oral surgery ninety minutes 
after the procedure, although patients in the combination drug group 
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were four times more likely to report an ʻexcellent sedationʼ as compared 
with ʻgood, fair or poorʼ in the single drug group. Also of note was the fact 
that the combination group was less restless during the surgical 
procedure. 
 
(b) Propofol and a narcotic  
Modern day programmable infusion pumps that can be individualised to 
the patient (age, gender, weight, length of procedure) allow the infusion 
of propofol together with, but via a separate infusion pump, of an ultra-
short acting narcotic (remifentanyl) that establishes ICS. As the clinical 
effect of both drugs is ultra short, this technique allows very rapid post-
operative recovery once the infusion is turned off. Recovery is 
significantly faster than from a midazolam-induced sedation. The future 
may see this technique gaining acceptance over the use of the longer 
acting benzodiazepines. 
 
(iii) Multiple agents 
Although effective sedation can mostly be established using either a 
single agent or double agent technique, there may be a need for brief 
deepening of the sedation to cover times of noxious stimulation (tooth 
elevation, for example). A very short acting agent like propofol can be 
useful to provide brief deepening of base-line sedation to cover these 
noxious periods.  
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RISK FACTORS AND SAFETY OF INTRAVENOUS SEDATION 
 
Adverse outcomes (morbidity and mortality) under dental sedation is rare.  There 
have been only two deaths related to dental sedation in Australia over the past 
30 years. In America, with its large population, there have been a greater number 
of deaths and a review of published mortality under dental sedation provides 
information on potential high-risk situations that should be avoided in the private 
practice dental setting. 
 
Jastak and Peskin (1991) reported on 13 deaths under dental sedation in the 
dental office between 1974 and 1989 in the United States. Whilst many of the 
drugs used today differ from those used on this cohort, the data are still relevant 
to adverse events today. The authors examined 
(i) the age, sex and health of the patient 
(ii) dental procedure initiated and reported duration 
(iii) anaesthetic/sedative technique used 
(iv) monitoring and personnel used 
(v) drugs and doses administered 
(vi) type of complication and time of occurrence 
(vii) management and outcome 
in an attempt to uncover risk factors. They found that most patients were 
classified as ASA II or III, with significant pre-existing conditions such as obesity, 
cardiac disease and heavy smoking. Only two patients were classified as ASA I. 
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They identified significant underlying medical conditions (risk factors), in order of 
frequency, as: 
(i) obesity (3) 
(ii) cardiac disorder (3) 
(iii) heavy smoking (3) 
(iv) hypertension (2) 
(v) epilepsy (2) 
(vi) barbiturate allergy (1) 
(vii) local anesthetic allergy (1) 
(viii) anaemia (1) 
(ix) asthma (1) 
(x) chronic obstructive pulmonary disease (1) 
(xi) diabetes (1) 
(xii) upper respiratory tract infection (1) 
(xiii) hyperthyroidism (1) 
(xiv) bull neck (1) 
Several patients had multiple medical diagnoses.  Polypharmacy (defined here 
as the use of three or more drugs causing CNS depression) was frequent, with 
eight patients receiving 4.4 drugs. Most cases were carried out using a team 
approach with multiple personnel, but in all cases the dentist was the 
operator/sedationist and in none of the cases was an anaesthetist present.  All 
cases revealed a lack of intraoperative monitoring.  Four patients had no 
monitoring at all and a further two had occasional palpation of pulse only. The 
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main cause of morbid events appeared to be hypoxaemia, secondary to airway 
obstruction. Hypoxaemia, and not the drug or combination of drugs used, was the 
principal cause of unanticipated adverse outcomes in the peri-operative period. 
The authors felt that since hypoxaemia may occur during ICS, monitoring for its 
incipient onset is of critical importance. Patient selection, based on pre-existing 
systemic medical conditions, is also very important. The authors felt that sedation 
risks increased significantly in patients with an ASA score of greater than one. 
Extremes of age (paediatric, and over the fifth decade) was also associated with 
higher risk. Ten out of 13 cases were considered avoidable by use of appropriate 
patient selection, monitoring and timely response to the adverse event. 
 
Modern-day ICS uses different drugs to those used in the aforementioned study. 
In addition, non-invasive monitoring has become relatively inexpensive and 
readily available and is employed routinely. Perrott et al (2003) recently published 
a landmark report regarding the safety of office-based oral surgical sedation 
procedures. This prospective cohort study reported on 34,391 patients who 
underwent oral surgical procedures using various anaesthetic techniques, 
including local anaesthetic, intravenous conscious sedation and deep 
sedation/general anaesthesia (DS/GA) between January 2001 and December 
2001. There were no exclusion criteria for patients. The study is the largest of its 
kind and drew data from the six defined American Association of Oral and 
Maxillofacial Surgeons (AAOMS) districts in the USA. Participant surgeons had to 
be an AAOMS member involved in sedation and general anaesthesia, have 
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internet access and treat patients in an office based setting. Of 34,391 patients, 
5,321 were treated using intravenous conscious sedation. Twenty four thousand 
seven hundred and thirty seven (24,734) patients received deep sedation or 
general anaesthesia. Almost all patients fell into the ASA I or II classification. 
Most surgical procedures were third molar removal, dentoalveolar procedures or 
implant surgery. The most commonly used drugs were midazolam, fentanyl, 
methohexital and propofol. Most patients were monitored with pulse oximetry, 
blood pressure, ECG and about 17% used capnography in addition. In almost all 
of the ICS and DS/GA cohort, the surgeon was also the primary manager of the 
anaesthesia. Ninety eight point seven percent (98.7%) of patients reported no 
complications or problems. Complications that were reported were minor and 
self-limiting (1.3%) and no patients required hospitalization due to anaesthetic 
problems. The most common complication was vomiting, followed by prolonged 
recovery and syncope. These are the same common problems reported by 
Rogers (2005). Of note is the fact that although 96% of the time the surgeon also 
provided the sedation, at least two or three support personnel were utilised 
during ICS. The use of supplemental oxygen during ICS was recommended, as 
was measurement of at least three parameters (pulse oximetry, blood pressure 
and ECG). The authors concluded that intravenous conscious sedation was safe, 
and associated with a high level of patient satisfaction. This study is relevant to 
the Australian situation because most practising Australian dental sedationists 
have received formal post-graduate training in sedation, similar to that received 
by the American oral surgeons during their training. A similar safe outcome can 
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therefore be expected in Australia. 
 
Rogers (2005) published a follow up paper to the Perrot et al (2003) study. 
Rogers looked at 2,889 in-surgery intravenous sedations performed for oral 
surgical procedures between 1994 and 2001. This study is also relevant to the 
Australian model because:  
(i) the surgeon was the operator/sedationist  
(ii) he had received formal post-graduate training in ICS  
(iii) he and his staff completed annual CPR training  
(iv) he undertook Advanced Cardiovascular Life Support training biennially  
(v) the drugs used were midazolam, fentanyl and methohexital (propofol 
would be used in Australia).  
This level of staff and operator education and operating environment closely 
reflects the Australian model. All patients were monitored by a dedicated 
monitoring nurse using non-invasive blood pressure, pulse oximetry and ECG.  
There were no known deaths the week following surgery.  Of the 2,889 
procedures, 77 adverse events were recorded. The most common adverse 
events were syncope (26), restlessness (20) and nausea and vomiting (10). 
Rogers concludes that there is a “growing volume of literature supporting the 
continued administration of intravenous sedation by the operating surgeon”. 
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SECTION 2: RESEARCH PROJECT 
 
INTRODUCTION 
 
Midazolam, fentanyl and propofol all depress respiratory drive and increase risk 
of apnoea and as a consequence, hypoxaemia. Since in-surgery dental 
sedations should only be carried out on healthy, ambulatory patients (ASA I and 
II), one measure of safety is to examine the oxygen saturation levels recorded 
during ICS to ensure that patients are consistently being kept at normoxaemic 
levels, because it is hypoxaemia that poses the greatest risk of morbidity or 
mortality to this otherwise healthy population (Jastak & Peskin 1991). 
 
For the purposes of this audit, safe oxygen saturation levels were defined as 94% 
and above. There is no single safe saturation value that can be referenced to 
define normoxaemia. The safe value may vary from person to person, in 
accordance with the health status of that individual. For example, a person with 
chronic emphysema may have a saturation level of 87%, which is normal for 
them, but which would represent an acute hypoxaemic crisis in a healthy ASA I 
person. In the private practice dental setting, patients fall into the healthy, 
ambulatory ASA I or II category. Normal saturation levels in this group of patients 
are defined by Fearnley (1995) as: 
95% and above is normoxaemic, 
93 - 94% is mildly hypoxaemic, 
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90 - 92% is hypoxaemic and 
below 90% is seriously hypoxaemic. 
 
The oxyhaemoglobin de-saturation curve is sigmoidal, not linear and therefore, 
de-saturation occurs very rapidly once levels of 92% and below are reached. 
Rapid de-saturation is an adverse event and in-surgery dental sedations should 
operate with a margin of safety. Modern-day pulse oximeters are accurate to 
within 2% (Nickerson, Sarkisian & Tremper 1998). A value of 94% was therefore 
chosen, as it provides a 2% safety factor to cover the possible margin of error 
and hysteresis (lag in the reading displayed on the monitor) associated with the 
pulse oximeter reading.  
 
The University of Sydney, Faculty of Dentistry, Graduate Diploma in Clinical 
Dentistry (Sedation) teaches candidates to set their pulse oximeter alarms at 
94%. 
 
The pulse oximeter used in this study was calibrated annually by a certified bio-
technician. 
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AIMS OF THE INVESTIGATION 
 
The review of the literature established that hypoxaemia was the key risk factor 
during ICS. There is a paucity of published research on oxygen saturation levels 
maintained during ICS. The two most significant current studies on the outcome 
and safety of modern day ICS (Perrot et al 2003 & Rogers 2005) do not examine 
the safety of ICS based on oxygen saturation levels that were maintained. They 
summarise intra-operative and post-operative morbidity (nausea, syncope, 
delayed recovery, etc).  
 
The aim of this retrospective quality assurance audit was to determine whether 
safe saturation levels were consistently maintained during a pre-determined 
number of dental sedation procedures. Should the data confirm that safe oxygen 
levels can be consistently maintained, this would provide evidence to support the 
safety of ICS, since safety and avoidance of hypoxaemia go hand-in-hand.  
Should the data show that hypoxaemic events occurred commonly, this would 
bring the safety of ICS into question. 
 
Propofol can be a profound respiratory depressant, especially in doses used to 
induce general anaesthesia (120 - 200 milligram). The respiratory depressant 
effect is less in sub-anaesthetic doses (10 to 15 milligram). This audit examined 
a second patient cohort that received sub-anaesthetic doses of propofol, 
following the establishment of base-line sedation using midazolam and fentanyl. 
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Should the data confirm that the additional use of sub-anaesthetic doses of 
propofol was associated with an increase in exposure to hypoxaemic events, its 
use would have to be questioned because of its impact on safety. Should the use 
of propofol in sub-anaesthetic doses prove not to be associated with an increase 
in hypoxaemic events, this would add to our evidence base with regards to the 
safety and efficacy of this drug. 
 
The null hypothesis can be a useful tool in testing the significance of differences 
between treatment and control cohorts, such as the two cohorts described above. 
Depending on the data, the null hypothesis either will, or will not, be rejected as a 
viable possibility. The null hypothesis (H0) is that µ1 - µ2 = 0 where µ1 is the 
population that gets the drug being tested and µ2 is the control group. 
 
In the case of this retrospective audit, the null hypothesis would be: 
H0: there is no difference in oxygen saturation levels recorded between the 
midazolan/fentanyl cohort, and the midazolan/fentanyl/propofol cohort. 
 
µ1 is the cohort that received propofol in addition to midazolam and fentanyl. 
µ2 is the cohort that received midazolam and fentanyl only.  
 
The alternate hypothesis would be: 
H1 :  there is a difference in oxygen saturations recorded when propofol is used in 
addition to midazolam and fentanyl. 
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If µ1 - µ2 = 0, then we do not reject H0, the null hypothesis. Importantly, this does 
not necessarily mean that the null hypothesis is true, it only suggests that there is 
not sufficient evidence against H0 in favour of H1. 
 
As is evident in the RESULTS section of this thesis, the null hypothesis cannot 
be rejected because there was no significant difference between the saturation 
levels recorded for each sub-cohort (µ1 - µ2 = 0). It should be noted however, that 
the two population groups are quite different in make-up because of selection 
bias on the part of the sedationist. Indeed, younger, thinner, female patients in 
ASA classification I, were more likely to receive propofol (see Table 3). Had the 
two population groups been similar in make-up, then µ1 - µ2 may not have 
equaled 0, and the outcome of the hypothesis test may have been to reject H0 in 
favour of H1. 
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METHODOLOGY 
 
Approval to undertake the study: 
This analysis of human data required Human Resources Ethics Committee 
(HREC) approval prior to accessing and analyzing the data. Approval requires 
justification that the study adds value to the evidence base.  HREC approval was 
sought and received for the analysis of the de-identified patient data. All patients 
were 18 years and older. 
 
Preliminary analysis: 
A preliminary statistical analysis of the data collected from 100 sedations was 
carried out to determine the number of sedation cases required to give adequate 
power to the study. A cohort of 100 was divided up into 50 patients who received 
midazolam and fentanyl only, and 50 patients who received propofol in addition 
to the midazolam and fentanyl. The preliminary analysis determined that a total 
cohort of 3,500 sedation cases, divided into two sub-cohorts of 1,750 would 
provide the required power to the study. 
 
Patient data base: 
Archived dental sedation records, which were generated by a single dentist in 
private practice between 1996 and 2006, were accessed from secure storage. 
The data was retrieved and uploaded onto an Excel spreadsheet, and only after 
data analysis was completed, were the data de-identified. This allowed for review 
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of any patient record that required further scrutiny. For example, the few records 
that recorded oxygen saturation levels of below 90% were further assessed to 
see if any of these low readings were sequential. 
 
Recording the data: 
Although one dentist provided all sedations, several different nurses over the ten 
years of data collection recorded the data on a standardised personal and 
anaesthetic chart (Appendix 2). An initial, pre-sedation and pre-operative 
measurement of vital signs was recorded, and following the commencement of 
the ICS, additional recordings were made during the sedation procedure at five-
minute intervals. Weight was assessed preoperatively by self-reporting or it was 
estimated to the nearest 5 kilograms. 
Record was made of: 
Patient information: 
(i) Age 
(ii) Gender 
(iii) Weight  
Sedation data: 
(i) Dose midazolam 
(ii) Dose fentanyl 
(iii) Propofol (yes/no) 
(iv) ASA Classification (I or II) 
(v) Oxygen saturation levels 
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The required number of cases for each sub-cohort (1,750) was randomly 
selected from the data pool until the required number of cases was recorded. The 
recordings of oxygen saturations were divided into three categories:  
(i) less than 90% (acute hypoxemic crisis)  
(ii) between 90 and 93% (hypoxemic)  
(iii) 94% and above (normoxemic)   
 
Measuring equipment: 
A CritiCare 81001 monitor was attached to each patient to record oxygen 
saturation levels, capnography, blood pressure and ECG. The monitor was 
serviced and calibrated annually by a certified bio-technician. 
 
Methods: 
All sedations were used during oral surgical procedures. Patients were placed in 
a supine position and supplemental oxygen was provided via a nasal hood at a 
rate of 4 litres per minute (Hardeman, Sabol & Goldwasser 1990, Rozario et al 
2008). Supplemental oxygen was provided throughout the sedation and for at 
least the first 45 minutes from commencement of the sedation. If difficulty was 
experienced in maintaining post-procedural normoxaemic readings, a Hudson 
mask was placed on the patient until recovered and stable. A non-invasive 
monitor was used to provide pulse-oximetry, capnography, ECG and blood 
pressure monitoring (Tinker, Dull, Caplan, Ward & Cheney 1989).  
                                                
1 CritiCare Systems, Inc, 20925 Crossroads Circle, Suite 100 
Waukesha, WI 53186, USA 
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Intravenous access was established via a 23G cannula and a continuous saline 
drip was administered via intravenous infusion. Both sub-cohorts received 
midazolam first, which was administered slowly over a period of a few minutes to 
a dose of 2 to 5 milligrams and titrated until conscious sedation was established. 
Fentanyl was then administered slowly to a dose of 50 to 100 micrograms, based 
on patient response (Weaver 2002). Local anaesthetic was then administered.  
 
The first sub-cohort received additional titrated increments of midazolam during 
the procedure if required to deepen the sedation, but propofol was not used.  The 
second sub-cohort received propofol in addition to midazolam and fentanyl. 
Propofol was never given simultaneously with either midazolam or fentanyl and 
was only given after base-line sedation had been established. Propofol was given 
to this sub-cohort because of an operator-perceived need to briefly deepen the 
sedation to cover short periods of intense noxious stimulation, e.g. elevation of a 
tooth (Hendrickx, Eger, Sonner & Shafer, 2008). This was used, rather than using 
the slower acting and longer lasting midazolam, to deepen the sedation. Propofol 
was given in 10 to 15 milligram sub-anaesthetic increments.  
 
Nitrous oxide, in addition to oxygen, was provided to the patients via a Porter 
scavenging nasal hood during most sedations in the patient group 18 to 60 years 
of age. Maximum concentration of nitrous oxide was 33% (2/4 litres per minute). 
The significance of the additional use of nitrous oxide with regards to oxygen 
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saturation levels, lies in the fact that these patients were not receiving 100% 
supplemental oxygen, but rather 67% or greater. The lungs of older patients are 
not as efficient as the younger cohort, and for this reason, most patients over 60 
years received 100% oxygen. If difficulty was experienced in maintaining oxygen 
saturation levels at or above 94% with any patient, the nitrous oxide was turned 
off and the patient received 100% oxygen.  
  
The dental team comprised the dental sedationist, two nurses assisting with the 
surgical procedure and a dedicated monitoring nurse, experienced in sedation, 
outside the surgical circle. Vital signs and saturations were recorded at five-
minute intervals for a minimum of 45 minutes, or for at least 30 minutes after 
cessation of the procedure. The pulse oximeter alarm was set at 94%.   
 
Capnography was used during all sedations (Koniaris, Wilson, Drugas & 
Simmons 2003; Nager & Krauss 2008). The capnograph probe was inserted into 
the nasal mask. Used in this manner the sensor is in an open circuit (as opposed 
to a closed circuit with an intubated patient) and therefore the carbon dioxide 
concentrations that were recorded were inaccurate. Nonetheless, a waveform is 
generated on the monitor with each exhalation, which provides a visual reference 
of effective ventilation (Srinivasa & Kodall 2004). Because the circuit is open, a 
flat line on the capnograph trace is not necessarily an indication of apnoea (it 
could be an indication of mouth breathing) but it was used as a prompt for the 
monitoring nurse to ask the patient to take a breath, even if saturation levels were 
 38 
94% or greater. The use of a capnograph during intravenous sedation gave the 
sedation team warning that effective ventilation may not be occurring well before 
the pulse oximeter began to show signs of de-saturation (Sandlin 2002). 
Readings of less than 94% required the team to cease operations until effective 
ventilation and safe oxygen saturation levels were re-established. 
 
Gender-specific tertiles were used as categories that made it possible to create 
low, medium and high weight groups, where the categories are determined 
separately by gender. The analysis of the effect of low, medium and high weight 
on outcome permits all the subjects to be used, giving greater power to the 
statistical results. The gender-specific weight tertiles in kilograms are defined in 
Table 1 below. 
 
Table 1: Gender-specific weight tertiles  
 
 
Gender Female Male 
Low less than or equal 60kg less than or equal 74kg 
 
Medium 61 to 68kg 
 
75 to 85kg 
 
High greater than 69kg greater than 86kg 
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RESULTS 
 
The total cohort of 3,500 cases generated 35,035 individual oxygen saturation 
readings. These readings are presented in the three defined categories of 
oxygen saturation levels and are also expressed as a percentage for each 
category in Table 2. 
 
Table 2:  Summary of the number and percentage of oxygen saturation readings 
recorded in each of the three defined saturation categories. 
 
 No propofol  
 
Propofol Total  
Number of SaO2 ≥ 94% 
 
17,288 
97.3% 
 
16,892 
97.9% 
 
34,180 
97.6% 
 
Number of SaO2 90-93% 
 
480 
2.7% 
 
350 
2.03% 
 
830 
2.37% 
 
Number of SaO2  <90% 
 
17 
0.095% 
 
8 
0.046% 
 
25 
0.07% 
 
Total for each category 17,785 
100% 
17,250 
100% 
35,035 
100% 
 
 
An adverse outcome (low saturations) was defined as two or more recordings of 
saturation levels less than 94% during the same ICS procedure. The records in 
the less than 90% category were examined to see if any patients had two or 
more sequential readings of less than 90% and none were sequential. Of the 25 
de-saturation levels recorded at less than 90%, four cases occurred at the start of 
the procedure, eight during the intra-operative phase and thirteen at the end of 
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the procedure, when the patient was not receiving supplemental oxygen and was 
conscious and communicative. Statistical analysis for each variable of interest 
was undertaken using: 
(i) Cross-tabulation of the variable by outcome  - two or more saturation 
readings of less than 94% (low saturations)  
(ii) Associated chi-squared test 
(iii) Corresponding logistic regression analysis together with odds ratio (OR), 
and 95% confidence interval (95%CI).  
 
A difference in patient profile was noted between the two sub-cohorts (propofol = 
no; propofol = yes).  
 
Table 3: Summary of the difference between the propofol and non-propofol sub-
cohorts 
 
VARIABLE CATEGORY Propofol 
Absent (%) 
(n=1750) 
Propofol 
Present (%) 
(n=1750) 
P 
VALUE* 
 
Gender Female 60.1 59.5 0.705  
  Male 39.9 40.5  
 Age <=25 21.1 38.9 <0.001  
 26-35 15.8 25.0  
  36-45 26.9 19.3  
  > 45 36.1 16.7  
Weight tertiles * 
(gender specific) 
      
0.325 
  Low (<= 60 female, <=74 male) 38.2 39.5  
  Medium (61 - 68 female, 75-85 
male) 
32.2 33.2  
  High (>=69 female, >=86 male) 29.6 27.3  
Midazolam Dose <=5 56.2 47.4 <0.001 
  > 5 and <=6  19.3 26.3  
   > 6 24.5 26.3  
ASA class I 92.1 96.0 <0.001 
  II 7.9 4.0  
* p-value for chi-squared test of association 
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Table 3 shows that younger, thinner, female patients in ASA class I were more 
likely to receive propofol. ASA II patients rarely received propofol. The exodontia 
patients predominantly underwent wisdom tooth removal and were mostly 
younger and propofol was used to mask the noxious stimulation experienced 
during tooth elevation. The second group underwent implant placement and 
propofol was rarely required. Implants were required mostly in the older patient 
group, who were heavier.  
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A summary of the analysis using cross-tabulation of the variable by outcome (two 
or more saturation readings <94%) is seen in Table 4 below. 
 
Table 4:  Table of the crude associations between the variables and the outcome. 
 
VARIABLE CATEGORY n % 
WITH 
LOW 
SATS 
OR(95%CI) P 
VALUE 
Gender Female* 2,093 3.5  Referent   
  Male 1,407 9.0 2.71 ( 2.02 to 3.64)  <0.001 
Age       <0.001# 
(years) <=25*  1,051 1.7 Referent   
 26-35 715 3.6 2.17 (1.18 to 3.98) 0.013 
  36-45  809 5.6 3.38 (1.94 to 5.89) <0.001 
  > 45  925 12.1 7.91 (4.77 to 13.12)  <0.001 
Weight 
tertiles**  
         
<0.001# 
 Low* 1,360 4.3 Referent   
  Medium  1,144 5.1 1.20 (0.83 to 1.74)  0.340 
  High  996 8.5 2.10 (1.48 to 2.96)  <0.001 
Midazolam 
dose (mg) 
         
0.031#  
 <=5* 1,814 6.7 Referent  
  > 5 and <=6   798 4.1 0.60 (0.41 to 0.90)  0.012 
   > 6  888 5.3 0.78 (0.55 to 1.11)  0.165 
ASA class I*  3,292 5.6 Referent  
  II  208 8.7 1.61 (0.97 to 2.67) 0.065 
Propofol No*  1,750 6.9 Referent  
  Yes  1,750 4.6 0.66 (0.49 to 0.88) 0.005 
* reference category 
** the unequal numbers in the weight tertiles is due to the ʻlumpyʼ nature of the self-reported or 
estimated weights. 
# p-values for test of overall homogeneity of risk if more than two levels for a factor 
 
The association of the variables gender, age, gender-specific weight, dose of 
midazolam, ASA class, and use of propofol, to the exposure of two or more low 
saturation events, is as follows: 
(i) Gender: Males were almost three times more likely to experience low 
saturations than females. 
(ii) Age: The chance of experiencing low saturation levels increased with 
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age.  Using 25 years of age or less as the reference category, the 26 
to 35 year-olds were twice as likely to experience low saturations, the 
36 to 45- year-olds more than three times as likely, and the over 45 
year-olds nearly eight times more likely to experience low saturation 
levels. 
(iii) Weight: There was no significant difference in the risk of low 
saturation levels between the low and medium gender-specific 
weight groups. The high weight group was nearly twice as likely as 
the low weight group to experience low saturation levels. 
(iv) Midazolam dose: An increase in the dose of midazolam was not 
associated with an increase in the chance of experiencing two or 
more low saturation events.  Fifty percent (50%) of patients required 
5 milligrams or less for their sedation procedure. 
(v) ASA class: There was little difference in the risk of an ASA I or an  
ASA II patient experiencing low saturation levels. 
(vi) Propofol: The use of propofol in addition to midazolam and fentanyl 
was not a factor in the chance of a patient experiencing low 
saturation levels. The propofol group had 2% less exposure to low 
saturation levels. Based on this data, there is no evidence to suggest 
that the additional use of sub-anaesthetic doses of propofol 
increases the risk of exposing a patient to multiple low saturation 
events. 
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Multiple logistic regression analysis of the data was also carried out. Table 5 
shows a multiple logistic regression model, adjusting for all variables. This did not 
show any indication of a significant propofol effect (OR=0.921, 95%CI 0.678 to 
1.253, p=0.601). 
 
Table 5: Multiple logistic regression analysis of low saturations and putative 
variables. 
 
Variables p-value OR 95.0% CI for OR 
    Lower Upper 
 Gender (* female) <0.001 2.777 2.048 3.765 
  Age groups  <0.001#    
     25 and less (*)   Referent   
     26-35yrs  0.035 1.937 1.048 3.581 
     36-50yrs  <0.001 2.938 1.662 5.196 
     > 50yrs  <0.001 6.613 3.875 11.286 
  Weight tertiles <0.001#    
     <=60 female, <=74 male (*)  Referent   
     61 – 68 female, 75 – 85 male 0.796 0.950 0.646 1.398 
     > 68 female, > 85 male 0.004 1.711 1.190 2.458 
  Midazolam group 0.338#    
     <=5mg (*)  Referent   
     > 5, <=6mg 0.178 0.752 0.497 1.138 
      > 6mg 0.333 0.833 0.575 1.207 
  ASA class (* 1) 0.424 0.805 0.474 1.369 
  Propofol (* no) 0.601 0.921 0.678 1.253 
*  reference category  
# p value for test of overall homogeneity of risk if more than two levels for a factor 
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Backward stepwise variable selection using likelihood ratio testing was used to 
identify the independent predictors of low saturation levels. The independent 
predictors were gender, age group and gender-specific weight tertile. The model 
including propofol and these independent predictors is shown in Table 6. 
 
Table 6: Multiple logistic regression model of low saturation levels including the 
independent predictors identified by backward stepwise elimination together with 
propofol. 
 
Variables p-value OR 95.0% CI for OR 
    Lower Upper 
 Gender (* female) <0.001 2.705 2.000 3.658 
  Age groups   <0.001#    
     25yrs and less (*)  1   
     26-35yrs    0.031 1.967 1.065 3.633 
     36-50yrs  <0.001 3.080 1.748 5.426 
     > 50yrs  <0.001 6.977 4.143 11.750 
  Weight tertiles  0.002#    
    <=60 female, <=74 male (*)    1   
     61 – 68 female, 75 – 85 male   0.675 0.921 0.628 1.352 
     > 68 female, > 85 male   0.007 1.633 1.144 2.333 
  Propofol (* no)   0.671 0.936 0.688 1.272 
* reference category 
# p value for test of overall homogeneity of risk if more than two levels for a factor 
  
Gender, age and weight are potential confounding variables but the OR 
associated with propofol use, after adjusting for the effects of these variables, 
remained not statistically significant and less than 1 (adjusted OR=0.936, 95%CI 
0.688 to 1.272, p=0.671). 
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DISCUSSION 
 
There are two fundamental requirements that must be fulfilled in order to avoid 
an adverse outcome during conscious intravenous sedation. Firstly, the 
haemodynamics must be stable, and secondly, there must be continuous, 
effective ventilation.   
 
Neither midazolam, fentanyl nor propofol cause significant change in patient 
haemodynamics at the low doses that are used for ICS. Dental surgery results in 
only relatively minor blood loss and little change in haemodynamics.  
 
The key to avoidance of adverse outcomes during conscious intravenous 
sedation lies in continuous, effective ventilation that avoids exposure of the 
patient to periods of hypoxaemia. 
 
Therefore, a retrospective analysis of oxygen saturation readings recorded during 
dental sedations is a valid measure of the safety of dental sedation. The properly 
monitored patient cohort ASA I and II should not experience an adverse 
hypoxaemic event, when sedated within RACDS/ANZCA PS21 guidelines. This is 
especially true when capnography is employed because it gives a visual trace on 
the monitor that effective ventilation is taking place.  
 
The sedation technique used in this study provided spontaneous, effective 
 47 
ventilation, with communication possible throughout the procedures. Should the 
results of such a review reveal that hypoxaemic events were common-place, then 
a reappraisal of current techniques and drug regimes would be required. 
 
All sedative and anaesthetic agents suppress respiratory drive. Therefore, if not 
carefully monitored and controlled, hypoxaemia remains the one factor that has 
the potential to cause serious complications or even mortality. Midazolam by 
itself has the least depressive effect on respiratory drive. However, the addition of 
a narcotic (such as fentanyl) significantly suppresses respiratory drive (Milgrom 
et al 1993). Propofol was developed as a general anaesthetic induction agent 
and is a powerful respiratory depressant when used in the doses to induce 
general anaesthesia. In low dose, propofol may be used safely, however some 
still regard it as a drug suitable for use only by anaesthetists (Appendix 3, PS9). 
 
The literature supports the fact that propofol can be used to provide conscious 
intravenous sedation (Horiuchi, Nakayama, Hidaka, Ichise, Kajiyama & Tanaka 
2009). Propofol has other useful and beneficial effects when used in sub-
anaesthetic doses of 10 to 15 milligrams. Borgeat, Oliver, Wilder-Smith and Suter 
(1994) examined the non-hypnotic applications of propofol. Several useful effects 
were reported on and these include:  
(i) ten to fifteen milligrams (10 - 15mg) of intravenous propofol was 
effective in preventing and treating postoperative nausea.  Onset of 
effect was rapid and there were no serious side effects. Duration of 
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effect was over 30 minutes in 70% of patients.  
(ii) narcotic induced pruritus may cause the patient to scratch their nose, 
interfering with an optimal working environment. Eighty four percent 
(84%) of patients who received 10 milligrams of propofol, as compared 
to the placebo group (16%), reported reduction in itch and the clinical 
effect was for 40 minutes to an hour.   Ninety percent (90%) of the 
placebo group who did not respond to the placebo had a positive 
response to a dose of propofol.  
(iii) propofol possesses anticonvulsant properties, although the dosage 
needed remains unclear.  
(iv) propofol is an anxiolytic.  A 10 milligram, sub-hypnotic dose of propofol 
provided effective anxiolysis as compared to placebo.  
(v) propofol is euphoric in sub-anaesthetic doses and may cause amorous 
behaviour or intense dreaming.  It therefore has abuse potential.   
(vi) propofol may have analgesic properties, with some authors reporting a 
reduction in need for post-operative analgesia.  
The authors conclude that because of the favourable pharmacokinetic properties 
of propofol, use of low doses for its antiemetic, antipruritic and anxiolytic is safe in 
clinical practice and devoid of serious side effects. 
 
A more recent paper by Vasileiou, Xanthos, Koudouna, Perrea, Klonaris, 
Katsargyris and Papadimitriou (2009) also examined the non-anaesthetic effects 
of propofol. Propofolʼs quick onset and rapid emergence is acknowledged.  Some 
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of the secondary effects discussed in this paper are not relevant to the dental 
sedation setting.  The authors did note propofolʼs direct antiemetic effect.  
Propofol was also shown to produce a significant reduction in pain in sub-
anaesthetic doses.  The anxiolysis-like profile was noted, as was its amnesic 
properties. The non-anaesthetic properties require further investigation that may 
expand its pharmacological and clinical use. 
 
Analysis of the data presented in this thesis demonstrated that the addition of 
propofol did not result in an increased risk of recording two or more saturation 
levels of less than 94% (low saturations) during the sedation procedure. Of the 
35,035 oxygen saturation readings recorded, only 25 were below 90%. Specific 
examination of these 25 case records showed that no desaturations were 
sequential (there were normal readings on either side of the single low reading) 
and none were associated with an adverse outcome.  
 
It is the authorʼs opinion that strict adherence to the guidelines of PS21 for 
conscious sedation as well as the use of a capnographic trace to detect apnoea, 
is the reason for the very low number of saturation readings recorded below 90%. 
 
Risk factors associated with low saturations were examined. These included: 
gender, age and weight.  
 
(i) Gender: Males were almost three times more likely than females to 
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experience low saturations at any given dose of midazolam, with or 
without propofol. This is possibly due to the fact that males smoke more 
than females (Australian Institute of Health and Welfare 2005). 
Unfortunately, no record was made of this variable when the data was 
recorded and this is unfortunate, as the information was noted on the 
patient medical history. Any future studies should record this 
information for analysis.  
(ii) Age: The younger patient cohort has a very low risk (1.7%) of 
experiencing two or more de-saturation events. This finding is in 
keeping with the cardiopulmonary health of this cohort. Risk increased 
with increasing age. By 45 years of age, the odds ratio of experiencing 
two or more de-saturation events increased to nearly 8.00 (95%CI). 
This means that the older group of patients should routinely receive 
100% oxygen to reduce risk, preferably without the additional use of 
nitrous oxide, which reduces the concentration of oxygen in the 
inhalation mix (Yano, Lishi, Tatsuta, Sakai, Narahara & Omori 1998; 
Yilmaz, Aydin, Karasu, Gunsar & Ozutemiz 2003; Muller, Prolla, 
Maguilnik & Breyer 2004).  
(iii)  Weight: The author did not record patient height, therefore body mass 
index (BMI) could not be calculated and examined as a variable. 
Gender specific weight posed a risk factor for the high weight groups 
only, which doubled the risk.  Hovagim et al (1989) found that a BMI 
greater than 30 posed a similar risk factor. Patient record (Appendix 2) 
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should include height so that the BMI can be calculated for future 
studies. 
 
Non-risk factors were found to be: the dose of midazolam, ASA classification 
(I or II) and use of propofol.  
 
(i) Dose of midazolam: Approximately half the total cohort received 5 
milligrams of midazolam or less, whilst 23% received 6 milligrams and 
26% received greater than 6 milligrams. The highest dose used on any 
patient was 15 milligrams. No correlation was found between the dose 
of midazolam that the patients received and the risk of experiencing two 
or more low saturation readings. The author believes that this is 
because all sedations were conscious and the drug(s) were carefully 
titrated.  Bolus doses of any drug were never given; rather the drug was 
titrated slowly to the desired endpoint.  Midazolam was also the drug 
that was given first, and if initially there were signs of over-sedation or 
respiratory depression, the administration of the narcotic was delayed 
or reduced (167 patients received 50 milligrams of fentanyl or less). 
 
(ii) ASA Classification: The ASA classification was developed as a means 
of determining the risk that a general anaesthetic posed to a patient. 
The classification was not developed to determine the risk of 
experiencing low oxygen saturations during conscious sedation. The 
 52 
results of this study show that the use of the ASA classification to 
determine the risk of experiencing low saturations during ICS was not 
predictive. Rather, age, weight and gender are factors that should be 
used to determine the risk of developing hypoxaemia. Accepting that in 
Australia dentists should only be sedating ASA I and II patients, the 
author suggests that the most meaningful determination of patient risk 
should include the use of the acronym ʻWAGʼ (weight, age and gender) 
as a guide to determining risk during ICS (chance of exposure to 
hypoxaemia).  
 
(iii) Propofol: This drug can have a profound short-term depressive effect on 
respiratory drive. It is therefore interesting to note that the propofol sub-
cohort did not have a higher incidence of experiencing low saturations. 
The use of propofol allows a lower initial dose of midazolam to be given 
– in other words, the ʻbase-line sedation depthʼ can be kept quite light, 
and brief periods of noxious stimulation can be covered by small, sub-
anaesthetic doses of propofol. This is especially effective as painful 
stimuli are covered by the use of local anaesthesia. In these small 
doses, the deepening of the sedation that propofol provides is of short 
duration only (not more than one or two minutes) and a fully saturated 
patient will not de-saturate within this short period, even if the propofol 
causes brief respiratory depression or apnoea. All patients were 
monitored using capnography, and the use of capnography has been 
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shown to improve our ability to monitor apnoea and reduce patient 
exposure to hypoxaemia (Heuss, Schnieper, Drewe, Pflimlin & 
Beglinger 2003). 
 
The primary limitation of this study lies in the fact that one operator/sedationist 
generated all the data. It would be useful for other dental sedationists to 
undertake similar audits of oxygen saturation levels recorded, which would add to 
the evidence base.  In addition, retrospective and case-control studies are also 
relatively low in the hierarchy of evidence. 
 
Accepting these limitations, the data support that a single operator/sedationist, 
working within the RACDS/ANZCA document PS21 guidelines, and supported by 
a team of experienced dental nurses, can consistently maintain safe oxygen 
saturation levels regardless of age, gender, gender-specific weight, dose of 
midazolam, ASA class (I or II) or the additional use of propofol.   
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CONCLUSION 
 
The following conclusions may be made from the literature review and from 
analysis of the data collected for this study: 
 
(i) Intravenous sedation can provide efficient and effective pain and 
anxiety management for procedures that would otherwise require a 
general anaesthetic environment. 
 
(ii) A review of the current literature shows that intravenous conscious 
sedation is safe with a high-level of patient and operator satisfaction. 
 
(iii) Exposure to hypoxaemia remains the single most potentially life-
threatening risk-factor. 
 
(iv) This study found that: 
• Males were almost three times more likely to experience low 
saturations than females. 
• The chance of experiencing low saturations increased with age.  
• High weight groups are nearly twice as likely as low weight groups 
to experience low saturations. 
• An increase in the dose of midazolam was not associated with an 
increase in the chance of experiencing two or more low saturation 
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events.  
• There is little difference within the ASA I and II classes, in the risk of 
a patient experiencing low saturations.  
• The use of propofol in addition to midazolam and fentanyl did not 
increase the risk of experiencing two or more events of low 
saturations.  
 
This retrospective audit of oxygen saturation levels recorded during dental 
intravenous sedations adds to our evidence base with regards to the safety of 
ICS when performed by an appropriately trained operator/sedationist. The risk of 
experiencing two or more hypoxaemic events that the additional use of propofol 
may or may not pose, and the possible effect of age, gender, weight, ASA 
classification and midazolam dose were analysed. These results should assist 
both dentists and anaesthetists to form an evidence-based opinion. 
 
 
 
 
 
 
 
